摘要
目的探讨艾塞那肽与门冬胰岛素30在口服降糖药控制不佳的肥胖2型糖尿病患者中的疗效及不良反应。方法选择口服降糖药血糖控制不佳的肥胖2型糖尿病患者60例,随机分为2组。对照组30例在原治疗基础上加用门冬胰岛素30注射液治疗,观察组30例在原治疗基础上加用艾塞那肽注射液治疗;治疗12周后,比较2组患者空腹血糖(FBG)、餐后2 h血糖(2h PG)、糖化血红蛋白(Hb A1c)、腰围、体重指数(BMI)。结果治疗后,2组患者FBG、2h PG和Hb A1c均较治疗前下降(P<0.05);治疗后,观察组与治疗组FBG、2h PG和Hb A1c比较,差异无统计学意义。观察组腰围和BMI治疗后均下降(P<0.05),对照组上述指标治疗后无明显下降;治疗后,观察组腰围和BMI均较对照组低(P<0.05)。结论应用艾塞那肽治疗口服降糖药物疗效欠佳的肥胖2型糖尿病患者后,患者血糖显著下降,达到与应用门冬胰岛素30治疗相同的降血糖效果,且在患者体重控制方面更具有优势。
Objective To evaluate the clinical efficacy and adverse reactions of exenatide and dual-phase insulin aspart 30 for obese type 2 diabetic patients on oral antidiabetic drugs with poor glycemic control. Methods Total sixty obese type 2 diabetic patients on oral antidiabetic drugs with poor glycemic control were enrolled in this study, all patients were randomly divided into two groups： 30 cases as control group were treated by the basic treatment and dual-phase insulin aspart 30 injection, and 30 cases as observation group were treated by the basic treatment and exenatide injection; waist circumference （WC）, body mass index （BMI）, fasting blood glucose （FBG）, postprandial blood glucose （2hPG）, glycated hemoglobin （HbA1c） and other indicators were compared between the two groups after 12 weeks treatment. Results Indicators were compared between before and after treatment, FPG, 2hPG and HbA1c levels were significantly lower in all patients （P〈0.05）; after treatment, the differences of FBG, 2hPG and HbA1c between two groups was not statistically significant. Compared with before treatment, WC and BMI were significantly lower in observation group （P〈0.05）, but the difference was not statistically significant in control group; after treatment, WC and BMI in observation group were significantly lower than which in control group （P〈0.05）. Conclusion For obese type 2 diabetic patients on oral antidiabetic drugs with poor glycemic control, exenatide can achieve the same hypoglycemic comtrol comparing with application of dual-phase insulin aspart 30 treatment, besides it has more advantages in improving weight control.
出处
《当代医学》
2016年第26期121-122,共2页
Contemporary Medicine
